In the phase 2 trial DESTINY-Breast01, HER2-positive breast cancer patients resistant, refractory or intolerant to T-DM1 are randomized into different DS-8201a dose level groups, to assess pharmacokinetics and recommended dose, followed by an expansion cohort (clinicaltrials.gov identifier: NCT03248492). This evidence concerns the gene ERBB2 and breast cancer.